(Q38317405)

2 September 2017

1 reference

title

The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects (English)

1 reference

2 September 2017

0 references

1 reference

3

Wim van den Brink

1 reference

2 September 2017

Jan van Amsterdam

1

1 reference

PubMed ID

25586398

2 September 2017

Tibor Brunt

series ordinal

2

1 reference

PubMed ID

25586398

2 September 2017

language of work or name

English

0 references

publication date

13 January 2015

1 reference

Journal of Psychopharmacology

2 September 2017

1 reference

2 September 2017

29

1 reference

2 September 2017

3

1 reference

2 September 2017

254-263

1 reference

CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts

2 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Silk Road: eBay for drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Patterns of synthetic cannabinoid use in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Spice: a new "legal" herbal mixture abused by young active duty military personnel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

AKI associated with synthetic cannabinoids: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabis and psychosis: what causes what?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

High-potency cannabis and the risk of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Development and preliminary validation of a plate-based CB1/CB2 receptor functional assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

The neurobiology and evolution of cannabinoid signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Beyond THC: The New Generation of Cannabinoid Designer Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Presynaptic, activity-dependent modulation of cannabinoid type 1 receptor-mediated inhibition of GABA release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Adolescent synthetic cathinone exposures reported to Texas poison centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Synthetic cannabinoid and marijuana exposures reported to poison centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Role of endogenous cannabinoids in synaptic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Neurocognitive consequences of marihuana--a comparison with pre-drug performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Purity of synthetic cannabinoids sold online for recreational use

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabinoids alter spontaneous firing, bursting, and cell synchrony of hippocampal principal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

"Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

College students and use of K2: an emerging drug of abuse in young persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

The emergence and analysis of synthetic cannabinoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Psychosis associated with synthetic cannabinoid agonists: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Synthetic legal intoxicating drugs: the emerging 'incense' and 'bath salt' phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Survey of current trends in the abuse of psychotropic substances and plants in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Legal controls on cannabimimetics: an international dilemma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Why do patients with psychosis use cannabis and are they ready to change their use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Emergency physicians' knowledge of cannabinoid designer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Severe toxicity following synthetic cannabinoid ingestion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabis Use and Earlier Onset of Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Requirement for CB1 but not GABAB receptors in the cholecystokinin mediated inhibition of GABA release from cholecystokinin expressing basket cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Spice: a never ending story?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. Armed Forces

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabis use and psychosis: theme introduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Prevalence and intensity of basic symptoms among cannabis users: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Myocardial infarction associated with use of the synthetic cannabinoid K2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

The impact of alcohol and illicit drugs on people with psychosis: the second Australian National Survey of Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabis, the mind and society: the hash realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

"Spiceophrenia": a systematic overview of "spice"-related psychopathological issues and a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

K2 toxicity: fatal case of psychiatric complications following AM2201 exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Marijuana, Spice 'herbal high', and early neural development: implications for rescheduling and legalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Psychoactive drug or mystical incense? Overview of the online available information on Spice products

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Convulsions associated with the use of a synthetic cannabinoid product

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

"Spice" girls: synthetic cannabinoid intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabis use at a young age is associated with psychotic experiences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabis with high cannabidiol content is associated with fewer psychotic experiences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Can recreational doses of THC produce significant dopamine release in the human striatum?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Synthetic cannabinoid use associated with acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Chemical analysis of synthetic cannabinoids as designer drugs in herbal products

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Generic legislation of new psychoactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabis use and psychosis: a longitudinal population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

A survey study to characterize use of Spice products (synthetic cannabinoids).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

A teenager with agitation: higher than she should have climbed

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Endocannabinoid signaling in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Psychosis due to "skunk".

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Cannabidiol monotherapy for treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Panic Attack after Spice Abuse in a Patient with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

Investigating a not-so-natural high

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565142

21 January 2018

Identifiers

DOI

10.1177/0269881114565142

1 reference

2 September 2017

1 reference

PubMed ID

25586398